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Abstract
Huntington’s disease (HD) is a progressive neurodegenerative hereditary disease clinically characterised by the
presence of involuntary movements, behavioural problems and cognitive decline. The disease-onset is usually
between 30 and 50 years of age. HD is a rare disorder affecting approximately 1.3 in 10,000 people in the
European Union. It is caused by an expanded CAG repeat in the first exon of the Huntingtin (HTT) gene, leading
to an abnormal form of the Huntingtin protein (Htt) (polyQHtt), containing N-terminus, enlarged polyglutamine
strands of variable length that stick together to form aggregates and nuclear inclusions in the damaged brain cells.
Treatments currently used for Huntington’s disease are symptomatic and aimed at temporally relieving the
symptoms of the disease; although some promising therapies are on study, there is no drug capable of stopping
disease progression either in the form of delaying onset or slowing disability progression. The utilization of peptides
interacting with polyQ stretches or with Htt protein to prevent misfolding and aggregation of the expanded polyQ
protein is a fascinating idea, because of low potential toxicity and ability to target very initial steps in the
pathophysiological cascade of the disease, such as aggregation or cleavage process. Indeed, several therapeutic
peptides have been developed and were found to significantly slow down the progression of symptoms in
experimental models of Huntington’s disease. This review is essentially focusing on the latest development
concerning peptide strategy. In particular, we focused on a 23aa peptide P42, which is a part of the Htt protein.
It is expected to work principally by preventing the abnormal Htt protein from sticking together, thereby
preventing pathological consequences of aggregation and improving the symptoms of the disease. In the
meantime, as P42 is part of the Htt protein, some therapeutic properties might be linked to the physiological
actions of the peptide itself, considered as a functional domain of the Htt protein.
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Background
Huntington’s disease (HD) is an autosomal-dominant,
progressive neurodegenerative disorder clinically charac-
terized by the presence of motor dysfunction (chorea,
dystonia, extrapyramidal rigidity and akinesia), cognitive
decline (early alteration of executive functions, mental
flexibility, and attention; later impairment of language,
visuospatial and memory functions), and neuropsychi-
atric symptoms (depression, apathy, anxiety, obsessive/
compulsive behaviours, irritable/aggressive symptoms
and sometimes personality changes, and psychosis).
Typically, onset of symptoms is in adulthood between 30
and 50 years, but the disorder can manifest at any time
between infancy and senescence [1, 2]. HD is a rare
disease and the highest prevalence is estimated to be
1.3/10.000 [3].
HD is caused by an expanded CAG repeat in the first
exon of the Huntingtin (HTT) gene [4]; the resulting
mutant protein in HD (polyQHtt) contains enlarged
polyglutamine repetitions of variable lengths, that stick
together and form intranuclear and intracytoplasmic
cellular deposits. In initial disease stages, cell loss and
reactive gliosis affect predominantly striatal medium
spiny neurons, while polyQHtt positive inclusions are
found in cortical region; in later disease stages cortical
cell loss is found [5–7]. Currently there is no curative
treatment for HD; only symptomatic pharmacological
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and non-pharmacological treatments are available with
some benefits mainly for motor and psychiatric HD
symptoms [8–11]. Unfortunately, there is no drug cap-
able of stopping disease progression either in the form
of delaying onset or slowing symptoms progression [12].
The precise physiopathology of HD is complex and
involves many mechanisms that have been described
[13, 14]: protein aggregation, alteration of protein degrad-
ation through autophagy [15] or ubiquitin-proteasome-
system (UPS) [16], enhanced proteolytic cleavages [17],
transcriptional deregulation and brain-derived nerve fac-
tor (BDNF) alteration [18], mitochondrial abnormalities
and defective energy metabolism [19–21], cytoskeletal de-
fects and axonal transport alterations [22, 23], loss of
wtHtt normal function [24, 25], non cell-autonomous de-
generation [26], and neuro-inflammation [27–29].
Based on these different pathogenic mechanisms, sev-
eral therapeutic approaches have been proposed to date
[30]. Among them, here we focus on peptide-based ap-
proaches that target different parts of the polyQHtt, pre-
venting aggregate formation of the polyQHtt proteins,
and that were further tested for their ability to rescue
abnormal cellular processes induced by the expanded
polyQ proteins.
Peptide-based therapeutic approach in HD and
polyglutamine diseases
The utilization of peptides interacting with polyQ
stretches or with Htt protein to prevent misfolding and
aggregation of the expanded polyQ protein is a prom-
ising intervention. A summary of the different pep-
tides developed up to now against HD is presented in
Tables 1, 2 and 3.
One of the first proposed peptide was a synthetic bi-
valent Htt-binding peptide containing two stretches of
short polyQ regions (25Q), separated by an alpha-helix
structure; it co-localized with aggregate of polyQHtt
protein and interacted with the polyQHtt. This peptide
was able to reduce and delay aggregate formation in a
cellular HD model (COS-1 hHtt17aa-103Q); moreover it
increased survival, reduced eye aggregate formation and
degeneration, and inhibited brain aggregate formation in
Drosophila HD models [31].
Polyglutamine binding peptide 1 (QBP1) is a 11 aa
synthetic peptide identified by a combinatorial screening
approach for its specific binding affinity to abnormal ex-
panded polyQ stretch [32]. QBP1 was able to co-localize
with and to reduce aggregate formation in cultured cells;
in Drosophila HD model it increased survival and de-
creased eye degeneration and aggregate formation [33].
To allow its efficient cellular delivery, QBP1 was conju-
gated to short peptides belonging to the group of the
peptide transduction domains (PTD) or cell penetrating
peptides (CPP), like the Penetratin part of Antennapedia
(Antp) [34] or of the HIV TAT-derived protein, allowing
the access to the cytoplasm and the nucleus after their
internalization by living cells [35–38]. This technique
overcame the problems of intestinal membrane passage
and increased bioavailability after administration of the
modified peptide in Drosophila food: oral administration
of Antp-QBP1 to polyQ-Macado Joseph Disease (MJD)
flies, a Drosophila model of the polyQ-induced spinocere-
bellar ataxia 3 disease (SCA3), remarkably delayed prema-
ture adult flies death; in addition, polyQ-MJD flies
administered with Antp-QBP1 had significantly fewer
polyQ aggregates in the eye imaginal disc of third instar
larvae, compared to the control flies [39]. The therapeutic
effect of Antp-QBP1 administration was also tested on a
R6/2 mouse model of the polyQ disease [40]: intraperito-
neal injection of Antp-QBP1 resulted in a slight improve-
ment of the weight loss, but did not improve the other
phenotypes such as motor dysfunction and premature
death; no significant decrease of polyQ inclusion body
formation could be detected. After intra-cerebroventricular
and intra-striatal injection of Antp-QBP1 or TAT-QBP1
peptides into wild type (wt) C57BL/6 mouse, PTD-QBP1
showed limited diffusion into the brain, restricted to
a few cell layers around the ventricles with however a
more efficient diffusion for Antp-QBP1. After either intra-
peritoneal or intracarotid arterial injection, no detectable
levels of PTD-QBP1 were found into the brain. The au-
thors suggested that lack of efficacy was due either to low
targeting of PTD-QBP1 into the brain or to a too severe
phenotype in the R6/2 mouse model [40].
More recently, a caspase-6 inhibiting peptide, targeting
the cleavage of the polyQHtt protein, a key step in HD
pathogenesis, was proposed and tested on the full-length
97Q-mHtt transgenic BACHD mouse model [41]. This
24aa peptide, called ED11, was designed on the basis of
the caspase-6 cleavage site in N-terminal part of Htt and
was able to inhibit caspase-6 activity by competing with
the caspase-6 active site on Htt; to enable cell penetra-
tion ability, the HIV TAT-derived peptide was used. The
authors accurately showed the selective caspase 6 interfer-
ence effect, with an only minor additional effect on
caspase 1 and 10 cleavage sites. Sub-cutaneous continuous
administration of ED11 with a minipump at a pre-
symptomatic stage showed restoration of body weight,
preserved motor performances, less depressive behaviour
and improved cognitive deficits. At a post-symptomatic
stage, ED11 administration showed amelioration on motor
performances, cognition, and depression. Unfortunately,
in this full-length hHtt-97Q transgenic BACHD mouse
model, neither aggregation was detectable, nor significant
atrophy was found, making impossible the evaluation of
the efficacy of the ED11 peptide on these features. Import-
antly no toxicity in cell or in mouse after prolonged
administration was found [41].
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Table 1 Summary of the efficacy of the different peptides against HD
Peptide Target of the
peptide
Model Population Way of administration End point Method of evaluation Results
Bivalent Htt-binding
peptide (Kazantsev
et al., 2002) [31]
PolyQ
stretches
Cell culture COS-1 cells Co-transfection of hHtt17aa-
103Q ± bivalent Htt-binding
peptide
Aggregation % of aggregate-positive
transfected cells
Delayed aggregate formation:
37.6 % reduction at 48 h; no
reduction at 96 h





Survival Survival rate Significant increased survival








Quantification of the number
of rhabdomeres/ommatidium








Cell culture COS-7 cells Co-transfection of
45Q-/57Q-/81Q-YFP ±
QBP1-CFP
Aggregation % of aggregate-positive
transfected cells
Significant aggregate reduction,
more important with shorter polyQ






















Significant suppression of eye
degeneration












Survival Life span (adult flies) Significant increase in survival







COS-7 cells Co-transfection of 81Q-GFP ±
Antp-QBP1 provided in the
cell medium
Aggregation % of transfected cells forming
inclusion bodies
Significant reduction (from 42 %
to 30 %)
COS-7 cells Co-transfection of 57Q-GFP ±
TAT-QBP1 provided in the
cell medium
Cell survival Quantification of cell death Significant reduction of cell death



















R6/2 mice Long-term continuous
intraperitoneal administration
of either Antp-QBP1 (2 mg/week)
or saline from wk2
Motor
performances
Latency to fall with accelerating
rotarod (from wk5 to death)
No significant difference
Body weight Weight measure (from wk5
to death)
Significant weight increased
compared to saline-treated mice
from wk5 to 10
Survival Life span No significant difference
Long-term continuous
intraperitoneal administration
of either Antp-QBP1 (2 mg/week)
or saline from wk2


















Table 1 Summary of the efficacy of the different peptides against HD (Continued)
ED11 (Aharony
et al., 2015) [41]
Inhibitor of
caspase-6
Cell culture PC12 cells Inducible mHtt- 145Q ± TAT-ED11
provided in the cell medium
Survival Cell viability and cell death
assessment
Significant increased cell viability





(from wk5); continuous infusion
(4 mg/kg/day; subcutaneously
implanted mini-pump) of ED11
peptide vs vehicle in BACHD
mice and of vehicle in wt mice
Body weight
(excessive weight)
Weight measure Attenuation of weight gain
Motor
performances
Latency to fall with accelerating
rotarod (monthly from wk9)
Preserved motor performance




the forced swim test (FST)
(5 months of age)





Open field test (wk22): total
travelled distance; time spent
in the centre and number of
transitions to the centre
Unchanged basal locomotor
activity; lower anxiety levels and
improved exploratory behaviour in










Not evaluable (no detectable
aggregates in untreated mice)
Post-symptomatic treatment
(from w36); continuous infusion
(4 mg/kg/day; subcutaneously
implanted mini-pump) of ED11
peptide vs vehicle in BACHD
mice and of vehicle in wt mice
Motor
performances
Latency to fall with accelerating
rotarod (monthly, wk30 to 44)
Increased motor performance




the forced swim test (FST)
(11 months of age)
Rescue at the level of wt littermates
Cognitive deficits Swimming T-maze test; shifting
abilities (time to reach the
re-located hidden platform)
Rescue at the level of wt littermates
Brain atrophy MRI volumetric measurements
(12 months of age)
Not evaluable (no significant
atrophy in untreated BACHD mice)
Legend: to characterize Htt fragments we use the general indication HttXaa-YQ: the length of the fragment is expressed as a number X of amino acids (aa) (superimposed); the length of polyQ expansion is expressed
















Table 2 Summary of the efficacy of the different intrabodies against HD
Antibody Target of
the peptide











Aggregation % of aggregate-positive
transfected cells








-25/72Q-GFP ± C4 intrabody
Cell survival % of co-transfected died or
dying cells
Rescue to wt level
Drosophila model






Survival % of survival to adult (eclosion);
mean, median, and maximal
lifespan
Increased survival to
adulthood (from 23 % to
100 %); increased mean

















et al., 2010) [47]
B6.HD6/1 125Q
(hHttex1-125Q)
C4 intrabody with AAV vector
into the striatum; presymptomatic
(injection: wk5 to 8 ; killed at
wk16 to 32); symptomatic (injection
wk 10 to 24; killed 8 to 10 wk later)














Cell culture (Colby et al.,
2004) [48]
HEK293 Co-tranfection: hHttex1-97Q-GFP +
empty vector or VL12.3




(Southwell et al., 2008) [49]
HEK293 Co-transfection: hHttex1-103Q-GFP +
empty vector or VL12.3
Aggregation Immunostaining Dose-dependent
aggregate reduction













-SNAP tag ± VL12.3
hHttex1-103Q
turnover
Fluorescence intensity of SNAP-tag No effect on polyQ
turnover
Cortico-striatal brain slice
model (Southwell et al.,
2008) [49]
Rat brain slices Co-transfection: YFP as
morphometric marker ± hHttex1
-103Q -CFP ± VL12.3
Neurodegeneration Immunostaining: counting of

































Table 2 Summary of the efficacy of the different intrabodies against HD (Continued)
Mouse model (Southwell




HD model: Unilateral striatal
injection: hHttex1-103Q -GFP or
GFP lentivirus.
Treatment: + VL12.3- AAV or




Ipsilateral rotations tested during
30’ after intraperitoneal
amphetamine injection.
Strong reduction of the
number of ipsilateral
rotations to the levels of
GFP lentivirus injected
animals
MSNs loss DARPP-32 staining Rescue to the levels of
GFP lentivirus injected
animals









2-months-old male mice and wt
littermates injected bilaterally in




Rotarod latency to fall (monthly
from 3 to 7 months of age)
No effect
Beam-crossing performance










Novel object location and
novel object preference tests
(7-month-old mice)
No effect in both tests
Anxiety Open field test Non significant
amelioration
Brain atrophy Ventricular size assessment
(7-month-old mice)
No effect
Body weight Assessment monthly from 3




3-day-old male mice and wt
littermates: bilateral injection
at the center of each forebrain
hemisphere of GFP- or VL12.3-AAV
Motor
performances
Rotarod latency to fall (weekly
from w4 to death)
Reduced latency to fall
(wk 10 to 12)
Beam-crossing performance
(weekly from w4 to death)
No rescue: Increased
severity of the phenotype
(time to cross the beam)
Brain atrophy Ventricular size assessment
(10-wk-old mice)
No effect
Body weight Assessment weekly from
4 wk until death
No effect
Aggregation Striatal immunostaining with
anti-Htt MW8 (detect aggregates
only) and nuclear marker; counting
of positive foci (10 week-old mice)




















Table 2 Summary of the efficacy of the different intrabodies against HD (Continued)









et al., 2002) [50]
HEK293 Co-transfection: hHttex1-97Q-GFP








Cell survival TUNEL staining 33 % reduction of TUNEL
positive cells
Cell culture (Southwell
et al., 2008) [49]
HEK293 Co-transfection: hHttex1-103Q-
GFP + empty vector or MW7
Aggregation Immunostaining Aggregate reduction with
a threshold-effect











no effect on soluble wt
hHttex1-25Q
Co-transfection: hHttex1-103Q
-SNAP tag ± MW7
hHttex1-103Q
turnover







(Southwell et al., 2008) [49]
Rat brain slices Co-transfection: YFP ± hHttex1
-103Q -CFP ± MW7





















+ empty vector or Happ1-Happ3
Aggregation Immunostaining Dose-dependent
aggregate reduction











no effect on soluble wt
hHttex1-25Q
Co-transfection: hHttex1-103Q
-SNAP tag ± Happ1-Happ3
hHttex1-103Q
turnover






model (Southwell et al.,
2008) [49]
Rat brain slices Co-transfection: YFP as
morphometric marker ± hHttex1
-103Q -CFP ± Happ1-Happ3





























Table 2 Summary of the efficacy of the different intrabodies against HD (Continued)
Mouse model (Southwell




HD model: Unilateral striatal
injection: hHttex1-103Q -GFP
or GFP lentivirus.
Treatment: + GFP- or Happ1-




Ipsilateral rotations tested during
30’ after intraperitoneal
amphetamine injection.
Strong reduction of the
number of ipsilateral
rotations to the levels of
GFP lentivirus injected
animals
MSNs loss DARPP-32 staining Rescue to the levels of
GFP lentivirus injected
animals
Aggregation Striatal immunostaining with anti-
Htt MW8 (detect aggregates only)








2-months-old male mice and
wt littermates injected bilaterally




Rotarod latency to fall (monthly
from 3 to 7 months of age)
Improvement in 3-, 4-,
and 7 –month-old mice
Beam-crossing performance
(monthly from 3 to 7 months
of age)
Partial improvement
Climbing (7-month-old mice) Increased climbing time










of spatial and cortical
learning
Anxiety Open field test Rescue to the level of wt
littermates




Body weight Assessment monthly from 3




3-day-old male mice and wt
littermates: bilateral injection
at the center of each forebrain
hemisphere of GFP- or Happ-AAV
Motor
performances
Rotarod latency to fall (weekly
from 4 wk until death)
Amelioration (between
w9 and 12 of age) vs
GFP-AVV injected animals.
Beam-crossing performance
(weekly from 4 wk until death)
Reduction of the time to
cross the 12 mm beam in
10- and 11-week-old
mice, and the 6 mm
beam between 9 and
11 weeks of age
Brain atrophy Ventricular size assessment
(10-wk-old mice)
Reduction of ventricular

















Table 2 Summary of the efficacy of the different intrabodies against HD (Continued)
Body weight Assessment weekly from 4 wk
until death
No effect
Aggregation Striatal immunostaining with
anti-Htt MW8 (detect aggregates
only) and nuclear marker;
counting of positive foci
(10 week-old mice).
Reduction of the number
of both neuropil and
intranuclear aggregates.





Four-week old male mice and
wt littermates: bilateral striatal
injection of GFP- or Happ1-AAV
Motor
performances
Latency to fall with accelerating
rotarod (every 2 wks from wk6
until death)
Significant improvement
from wk 20 to 40 at the
level of wt mice
Beam-crossing performance
(every 2 wks from wk6 until death)
Significant improvement
with reduction of time to
cross the three beams vs
GFP-AAV treated and wt
mice.
Clasping (22-week-old mice) Attenuation of clasping
behavior
Body weight Assessment every 2 wks from wk6
until death
Increased weight vs GFP-
AAV treated but not to
the level of wt littermates
(from wk 22)
Life span Once ill, twice a day assessment
of righting reflex
33 % increase of
maximum life-span (from





2-months-old male mice and
wt littermates: bilateral striatal
injection of GFP- or Happ1-AAV
Motor
performances
Rotarod latency to fall (monthly
from month 3 to 6)
Increased latency to fall
in 5- and 6- month-old
mice
Beam-crossing performances
(monthly from month 3 to 6)
Decrease time to cross
the beams at 5 and
6 months (28 mm beam)
and at month 6 (6 mm
beam)






Novel object location and novel
object preference tests (6-month-
old mice)
No effect

















Table 2 Summary of the efficacy of the different intrabodies against HD (Continued)




Body weight Assessment monthly (from 3 to










Cell culture HEK293 Co-transfection: hHtt208aa
23/130Q ± EM48















Immunostaining Significant reduction of
neuropil aggregates
Mouse model R6/2 (hhttex1-
144Q)









injected region; no effect
on intranuclear inclusion
N171-82Q Bilateral striatal injection of












Stride length (8-wk post
injection)
Improvement
Rotarod latency to fall (8-wk
post injection)
Significant improvement











Cell culture COS-1 Co-transfection: hHttex1
-51Q ± 1C2
Aggregation Filter retardation assay Up to 85 % reduction in
aggregates
Legend: To characterize Htt fragments we use the general indication HttXaa-YQ: the length of the fragment is expressed as a number X of amino acids (aa) (superimposed); the length of polyQ expansion is expressed
















Table 3 Summary of the efficacy of P42 in cellular, Drosophila, and mouse R6/2 HD models
Peptide Model Population Way of administration End point Method of evaluation Results
P42
(Arribat et al., 2013) [55]
Cell culture HeLa cells
(hHtt171aa-136Q)
Co-transfection: polyQHtt +
P42 or empty vector
Htt aggregation Immunostaining; filter
retardation assays
Rescue = 80 %
P42TAT
(Arribat et al., 2014) [61]
Cell culture HeLa cells
(hHtt171aa-136Q)
Co-transfection: polyQHtt +
P42TAT or empty vector
Htt aggregation Immunostaining; filter
retardation assays





Rescue = 90 % (P42TAT
concentration dependent)
P42
(Arribat et al., 2013) [55]
HD Drosophila MS-1096-Gal4; UAS-
HA-hHtt171aa-138Q




(L3 larval salivary glands)
Rescue = 80 %
GMR-Gal4; UAS-
hHttex1-93Q
Genetic cross: UAS-P42 vs
UAS- GFP (neutral control)
Eye toxicity Phenotypical comparative
analysis (eyes of adult flies)
Rescue = 100 %
OK6-Gal4/UAS-NPY-
GFP; UAS-hHtt548aa-128Q
Genetic cross: UAS-P42 vs
UAS-LacZ (neutral control)
Larval locomotion Locomotion (mm/min) Rescue close to 100 %
OK6-Gal4/UAS-NPY-
GFP; UAS-hHtt548aa-128Q
Genetic cross: UAS-P42 vs
UAS-LacZ (neutral control)
Axonal transport Immunostaining and live
imaging to quantify different
parameters of Neuropeptide
Y vesicles trafficking in larval
motoneurons.
Recovery of the different
parameters: Number of
vesicles: 28 %; % of
pausing: 21 %; velocity: 31 %
ELAV-Gal4; UAS-hHtt548aa
-128Q
Genetic cross: UAS-P42 vs
UAS-LacZ (neutral control)
Adult survival Mean, median, and maximal
survival (days)
Increased median survival
(day 18 to 26); no effect on
mean and maximal survival
P42TAT
(Arribat et al., 2014) [61]
R6/2 mice hHttex1-140Q Transmucosal daily administration
of P42TAT with Aonys® water-in-oil
microemulsion (600 μg/ml/kg) vs
empty microemulsion at pre-
symptomatic (wk2 to wk11) R6/2
and Wt mice.
Motor performance Latency to fall from accelerating




Clasping test Frequency and duration of the
foot-clasping posture (twice a
week at wk 7, 9, and 11)
Complete rescue vs placebo-
treated R6/2 and to wt mice
Weight loss Weight measure between
wk8 and wk10
Significant reversion of body





size of cortical and striatal
intranuclear aggregates;
cortical and striatal astrocyte
number
Significant 50 % reduction
of cortical and striatal
aggregates; non significant
reduction of the astrogliosis
Cerebral atrophy Lateral ventricle enlargement Rescue = 30 %
Legend: to characterize Htt fragments we use the general indication HttXaa-YQ: the length of the fragment is expressed as a number X of amino acids (aa) (superimposed); the length of polyQ expansion is expressed
















Monoclonal antibodies were also generated, such as
1C2 [42], able to specifically recognize the conform-
ation of an elongated polyQ form in soluble proteins,
but not the CAG sequence in insoluble aggregates of
polyQ proteins, suggesting that 1C2 reduced aggrega-
tion, probably by stabilizing the polyQ protein in a
native, soluble form and preventing aggregation-prone
conformational changes [43].
Finally, several intracellular antibodies, known as
intrabodies, binding to different part of the N-terminal
Htt have also been identified to date. The intrabodies
identified so far recognize a region in Htt other than the
polyQ stretch itself and are therefore potentially specific
for Htt protein, although cross-reactivity with other
proteins cannot be excluded. Some intrabodies, like
C4 [44–47] and VL12.3 [48] bind to the first 17aa of Htt
(N17 region): they act by preventing aggregation and form-
ing soluble complexes with the Htt-N-terminal part, which
subsequently may undergo normal protein turnover; the
levels of soluble wt and polyQHtt were therefore reported
as increased [45] or unchanged [49] (Table 2). Other intra-
bodies (HAPP1, HAPP3, and MW7) [49] [50, 51] bind to
the Proline Reach Region (PRR) domain: they act mainly
by enhancing the degradation of the mutant protein which
reduces soluble polyQHtt levels [49] (Table 2). Finally, an-
other intrabody (mEM48), directed to the Valine/Alanine
amino acid residues after the PRR tract, might alter the
conformation of mutant Htt, leading to its degradation via
the ubiquitin-proteasome system [52]. The expression of
these intrabodies was shown to be efficient in suppressing
Htt aggregation and neurodegeneration when tested in a
Drosophila model, through genetic expression in trans-
genic flies, [45] and in mouse models of HD, through con-
jugation with a viral vector and after an intra-striatal
injection [47, 51, 52] (Table 2). The use of intrabodies is
therefore an attractive therapeutic approach with regard to
their high binding affinity to the disease-causing proteins
and their potential specificity for HD. Moreover some
intrabodies are very small, therefore reducing problems of
immunogenicity and allowing the passage in nuclear pore;
this could be particular important considering the toxic
role of some cleaved N-terminal Htt fragments and their
nuclear localisation [53]. However, major concerns about
the therapeutic utilisation of intrabodies are the way of ad-
ministrations and the possible unfavourable side effects
due to cross-reactivity with the wild type Htt or to the fact
that they are non-physiological entities.
Globally antibody- or peptide-based therapies seem to
be very efficacious in ameliorating biological and clinical
features of HD in different models; major drawbacks for
their in vivo use are their rapid degradation by proteases
and their poor blood–brain barrier and cellular mem-
branes permeability, leading to an important difficulty in
targeting central nervous system (CNS) neurons.
Identification of the P42 peptide and efficacy on
cellular and Drosophila HD models
We have recently identified a new domain of Htt that is
also acting on aggregation. We first observed that the
548 aa N-terminal part of normal human Htt (hHtt) or
the 620 aa N-terminal part of Drosophila Htt homolog
(dHtt) were sufficient to prevent polyQHtt aggregation
in both HeLa cell and fly HD models [54]. Therefore, we
searched for N-terminal region peptides sharing homolo-
gies between the human and the fly Htt protein, and play-
ing a protective role on polyQHtt-induced phenotypes
[55]. We first sequentially screened peptides designed from
the hHtt protein, and identified a 23 aa peptide (P42) that
shared homologies with its Drosophila counterpart.
The P42 peptide (“AASSGVSTPGSAGHDIITEQPRS”)
is derived from the 480–502 aa region of the endogen-
ous hHtt and lies within a region rich in proteolytic sites
that play a critical role in the pathogenesis process
(Fig. 1a) [56–58]. When the P42 sequence was included in
an expressing vector and provided by co-transfection to
polyQHtt HeLa cells, it was able of inhibiting polyQHtt
aggregation, as efficiently as human longer peptides cover-
ing this domain: Htt-548aa or P4-166aa [55] (Fig. 1b). P42
was subsequently tested in Drosophila models of HD. To
this end, flies expressing polyQHtt were crossed with
transgenic flies expressing P42. P42 was found to reduce
polyQHtt cytoplasmic aggregates in larval salivary glands
and motoneurons, to ameliorate larval locomotion, and to
prevent the polyQHtt-induced alteration of vesicular traf-
ficking along the axons of larval motoneurons. P42 also
prevented polyQ-induced eye neurodegeneration, charac-
terized by eye depigmentation and abnormal ommatidial
arrays; P42 expression in transgenic polyQ flies does not
increase survival, although it ameliorates the median of
the survival [55] (Table 3).
Modifications of P42 and efficacy on cellular and
mouse HD models
Conjugation of P42 with a protein transduction domain
To overcome the problems of cell membrane penetra-
tion and brain delivery, we conjugated P42 to a cell
penetrating peptide (CPP), as already developed for
QBP1 [39, 40]. However, instead of using Antennapedia,
we used a 11-aa peptide (YGRKKRRQRRR) part of the
TAT protein, derived from the HIV; the same CPP was
subsequently conjugated to the caspase −6 inhibiting
ED11 peptide, and found efficient after intra-peritoneal
administration [41]. In HeLa cells expressing polyQHtt,
the fusion peptide P42-TAT supplemented in cell culture
medium was able to penetrate cells and prevent aggregate
formation [55] (Table 3); increasing concentrations of
P42-TAT synthetic peptide (from 0.1 μM to 20 μM) drove
a clear dose–response effect with a complete inhib-
ition of aggregation in presence of 10 μM peptide
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(Table 3). Note that even a 20-fold excess of this protective
dose only produced 25 % mortality, as assessed by the
MTT (3–(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) colorimetric test, while the IC50 value could
not be measured, suggesting a low toxicity of the
peptide on cell survival. In case of other small mole-
cules [43], intrabodies, [49, 50, 52], or peptides [41],
IC50 value was rather calculated in presence of
polyQHtt protein to measure their efficacy in block-
ing aggregation and cell toxicity.
Insertion of P42TAT into water-in-oil microemulsion,
transmucosal administration and efficacy on
mouse model
Although the conjugation to TAT overcame the problem
of cell membrane penetration, the issues of peptide
degradation, delivery to the central nervous system, and
non-invasive administration were still unresolved. In order
to optimize the pharmacokinetic characteristics of P42
(serum half life and distribution profile) and to provide a
non-invasive route for repetitive delivery of this fusion
peptide, we used a novel water-in-oil microemulsion drug
delivery vector named Aonys®, developed by Medesis
Pharma (France) [59, 60]. Aonys® provides a transmucosal
(buccal/rectal) route for drug administration which en-
hances CNS penetration [61]. This technology was also
used for efficient CNS targeting after systemic delivery of
lithium in a YAC128 mouse model of HD [62] and of
small interfering RNA (siRNA) in a mouse model of prion
disease [63]. The studies on P42 diffusivity showed that
3 h after intra-cerebroventricular injections of P42TAT in
wild-type C57BL/6 J mice, a tagged form of the peptide
(TAMRA-P42TAT) could widely diffuse and be found in
different neuronal populations (neurons and astrocytes)
and in different cellular compartments (nucleus and cyto-
plasm), in both the cortex and striatum. The same results
were obtained after transmucosal P42TAT water-in-oil
microemulsion administration. These data showed that
P42TAT has the ability to diffuse into the brain in the
different cell layers, including the striatum and that
P42-TAT is able to reach the brain when adminis-
trated orally via Aonys® microemulsion.
Fig. 1 The P42 peptide. A- Location of P42 peptide within the 548 aa N-terminal part of human Huntingtin (hHtt) protein. In the schematic
diagram the different domains are indicated: Polyglutamine tract (PolyQ), N17 and Proline rich (PRR) domains covering exon 1, as well as the
HEAT repeats; the sites of cleavage by caspase (in red), calpain (in green) or metallomatrixprotease (MMP); posttranslational modifications, such as
sumoylation (S), palmitoylation (palm), acetylation (Ac) and some of the phosphorylation (P) sites (modified from [76]). The amino acid sequence
of P42 is shown (in blue). B- Cultured HeLa cells co-transfected with polyQ-hHtt-GFP presenting cytoplasmic aggregates (in green); co-transfection
with polyQ-hHtt-GFP and P42 prevents aggregate formation [55]. C- Possible mechanism of action of P42 is an interaction with the Htt protein at
the N17 or at the Proline Reach region (PRR); interaction with the polyQ domain was excluded on the basis of lack of efficacy in other polyQ-induced
disease models [55]. Co-immunoprecipitation and BiFC experiments confirmed a direct interaction of P42 with N17.
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The protective effect of Aonys® -formulated fusion
peptide was tested in the R6/2 HD mouse model: know-
ing that symptoms appear at week 6 in these mice, daily
transmucosal administration of P42TAT was performed
at pre-symptomatic stage (from week 2 to week 11), and
was able to improve the motor performances and to re-
duce polyQ aggregation in the brain, weigh loss, and
brain atrophy; the administration of P42 was proved to
be efficacious in the R6/2 HD mouse leading to an im-
provement of at least 30 % recovery, according to the
phenotype analysed [61] (Table 3).
P42 mechanism of action on aggregation process
Protein aggregation is a multistep process requiring an
initial event, called nucleation, involving the N17 do-
main; during this nucleation step, polyQHtt adopts a
structure able to associate with itself, which leads to an
enhanced local concentration and oligomerization of the
mutant hHtt; because of the presence of abnormal ex-
panded polyQ stretches, these oligomers will further
form parallel ß sheets, seeding of the aggregation
process [64]. The presence of N17 domain was shown to
accelerate the aggregation process: intrabodies or pro-
teins targeting the N17 domain are able to suppress ag-
gregation and associated toxicity by inhibiting the initial
nucleation step [44, 45, 47, 65–67]. Intrabodies against
the PRR domain are also able to reduce polyQHtt aggre-
gation and toxicity, mainly increasing turnover rate of
mutant Htt [49, 51].
P42 showed to be able to improve phenotype in HD
model expressing an expanded polyQ exon1 containing
the N17, the PRR, and the polyQ domains, all playing a
role in polyQHtt aggregation, suggesting a possible dir-
ect interaction between P42 and one of these N-terminal
domains. Interestingly, genetic data from Drosophila
models highlighted that P42 is not able to counteract
eye degeneration in other polyQ-induced diseases differ-
ent from HD, indicating that P42 mechanism of action is
specific for Htt protein and therefore excluding an
interaction with the polyQ domain [55]. Indeed, prelimin-
ary data including co-IP experiments and Bimolecular
Fluorescent Complementation (BiFC) experiments suggest
that P42 directly interacts with the N17 domain, therefore
confirming the genetic data. This leads us to propose a
model in which the addition of exogenous P42 interferes
on aggregation process by blocking the initial step of
nucleation, through its direct interaction with the
N17 domain (Fig. 2).
However, the P42 mechanism of action could be more
complex and polymorph: as a part of the Htt protein, it
could be a functional protein domain and we cannot
exclude a therapeutic effect linked to its normal physio-
logical properties. Interestingly, P42 localised to the
Tubulin network in vivo in Drosophila cells [54], and
recently we confirmed that P42 binds microtubules
(unpublished results). As Htt protein is involved in axonal
trafficking [68] and P42 ameliorates the vesicular trans-
port along the axons [55], P42 could therefore have a
beneficial role modulating axonal transport, independently
of its direct effect on aggregation.
Conclusion
Promising therapeutics for HD are under evaluation, not-
ably nucleotide-based gene silencing methods. Both
adeno-associated virus (AAV2) vector expressing HTT-si-
lencing micro RNA (miRNA) [69] and intra-ventricular
delivered antisense oligonucleotides (ASO) [70] were able
to reduce the level of Htt mRNA and protein and to deter-
mine an amelioration on motor and behavioural features
in different mouse (YAC128, BACHD, R6/2), and non hu-
man primate models of HD. Importantly, these studies
showed an amelioration on already symptomatic mouse
models, suggesting the reversibility of some features of the
disease, although earlier treatments produce quicker and
more robust reversal of disease; moreover, these studies
showed that ASO injection determined a long-lasting
transient suppression of Htt protein level, overcoming the
period of ASO infusion, and that the amelioration of the
disease in turns was evident for an extended period of
time, exceeding the period of Htt suppression [70]. The
existence of a phase I trial with ASO in humans in
Amyotrophic Lateral Sclerosis [71] showing no acute
toxicity and the possibility to measure mHtt level in CSF
[72] in humans opened the way to a phase I study with
intrathecal ASO in symptomatic HD patients. However
some important issues are still opened such as selectivity
toward mHtt, consequences of a possible concomitant
lowering of normal Htt, sufficient targeting and diffusion
in the brain after CSF infusion [30].
Whereas peptides and ASO are targeting early events,
other new treatments are conceived with symptomatic-
only effect or targeting later pathophysiological events and
downwards interactors in the disease cascade, such as
BDNF, the sirtuin system, or innate inflammation [30, 73].
Peptide-based drugs have been recently introduced in
pipeline development and approved for therapy, notably
to treat gastrointestinal disorders, hematological cancer,
respiratory distress syndrome, Cushing syndrome, and
anaemia in chronic kidney disease [74]. Physiological
peptides can be biologically active and can be essential
component of cell signalling pathways, immune sys-
tem, hormonal systems, enzymatic systems and other
important systems in the body. In the case of neuro-
degenerative diseases, various routes of delivery can
be used: they could be injected to patients and newer
methods like intranasal delivery [75], but also oral/
rectal mucosal administrations, are presently under
investigation [61, 63].
Marelli and Maschat Orphanet Journal of Rare Diseases  (2016) 11:24 Page 14 of 18
Compared to other synthetic small molecule drugs,
physiological peptides might offer lower toxicity, higher
specificity, and fewer side effects [74]. Although most of
the peptides developed against HD are artificially–
conceived peptides, P42 has the advantage to be derived
from a sequence physiologically present in the Htt
protein; this could be important to limit possible adverse
events linked to immunogenicity.
As discussed in this review, peptide-based strategies
could be potentially very efficacious in HD treatment
because of their ability to target very initial steps in the
pathophysiological cascade of the disease, such as aggre-
gation or cleavage process. The efficacy of the different
peptides studied until now was demonstrated in different
models and on different phenotypes, including polyQHtt
aggregation, eye degeneration, survival, larval motility,
and axonal transport in the Drosophila HD model, and
motor phenotype, weight loss, cognitive performances,
cerebral polyQ aggregates, and cerebral atrophy in HD
mouse model (Tables 1, 2 and 3). R6/2 mice are one of
the models most frequently used to test peptide efficacy
since it recapitulates many features of the disease found in
humans with HD, such as intranuclear inclusion, weigh
loss, motor and cognitive impairment, and brain atrophy.
Remarkable results were obtained with peptide-based
therapies in the R6/2 model concerning motor performances,
body weight, aggregate formation, and brain atrophy; a
prolongation of the lifespan was however only observed in
the N171-82Q mouse model (Tables 1, 2 and 3). Other HD
mouse model, such as full-length hHtt-97Q BACHD or
YAC128 were most frequently used to test cognitive perfor-
mances or anxiety, but in these models, the correct evalu-
ation of the effect on Htt nuclear inclusions, brain
atrophy and weight was complicated by the presence of
milder or different (such as weight gain instead of weight
loss) phenotypes in these less aggressive HD models
(Tables 1 and 2). None of the peptide developed until
now has been tested in knock-in HD mouse -models.
Fig. 2 Model of action of P42. A- In pathologic conditions, cleavage of mutant polyQHtt is increased, leading to short N-terminal fragments
mostly lacking P42. N17 domains self interact, bringing together polyQHtt proteins (nucleation step). Oligomers will further form parallel ß sheets,
thereby enhancing the aggregation process [64]. B- Our model is that exogenous addition of P42 allows a protective effect of polyQHtt-induced defects
by directly interacting with the N17 domain of the N-terminal part of polyQHtt, therefore preventing nucleation, and consequently oligomer-
isation and aggregation processes.
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Up to now, peptide stability and ability to target the
central nervous system were major difficulties in the
development of peptide at therapeutic ends. These
problems were overcome during the development of P42
by conjugation with the TAT peptide transduction
domain and using the water-in-oil microemulsion system
developed by Aonys® technology. These strategies allowed
systemic non-invasive delivery associated with increased
peptide stability and efficacious targeting of the central
nervous system. Indeed, the association of P42 to TAT
and microemulsions allowed reducing the amount of
peripheral-administered peptide required to get sufficient
peptide level in the central nervous system; non-invasive
transmucosal oral administration could be an important
issue in the context of a potential chronic administration
to pre-symptomatic individuals to ensure patient compli-
ance; finally, peptide stability could be further ameliorated
and P42 administration can be potentially associated to
other treatments to improve HD prognosis.
P42 could be particularly interesting because of its
double role in targeting aggregation and in favouring
some physiological function of normal Htt, as it is
naturally part of the Htt protein. Although P42 seems ef-
ficacious mainly at a pre-symptomatic stage we also
found some effect at post-symptomatic stage in R6/2
mice, beginning treatments at week 7 when symptoms
already started. Notably, an efficacy on motor perfor-
mances and brain atrophy was observed after P42
administration to already symptomatic R6/2 mice.
Further investigations suggested a beneficial effect of
P42 on BDNF level, synaptic plasticity and neuronal ac-
tivity, behavioural and cognitive aspects of the disease
(unpublished results).
Therefore these results suggest that P42 offers a par-
ticular therapeutic potential not only by counteracting
the effect of the mutant mHtt protein, but also by en-
hancing the physiological performances of the normal
Htt protein. On the basis of these data P42 has recently
obtained the designation as orphan medication for HD
by the European Medicines Agency (EMA).
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